CALGB Manuscripts Published in 2004 sorted by Committee
(abstracts follow on separate page organized by ASH and ASCO)

9342
Breast Committee
Failure of higher-dose Paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
Journal of Clinical Oncology 22(11):2061-2068, 2004
7/4/2004

9343
Breast Committee
A randomized comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) carcinoma of the breast: results of CALGB study 9343
9/2/2004

Comprehensive CARE
Managing Accrual in Cooperative Group Clinical Trials
Demmy TL, Collyar D, Katz ML, Krasnov C, Borwhat MJ, Battershell A, Yasko JM, George SL
Journal of Clinical Oncology 22(15):2997-3002, 2004
8/1/2004

Comprehensive CARE
Oncology physician and nurse practices and attitudes regarding offering clinical trail results to study participants
Journal of the National Cancer Institute 96(8):629, 2004
4/21/2004

9473
CCHO-Symptom Control
Phase II study of fish oil capsules for patients with cancer cachexia; a Cancer and Leukemia Group B study
Burns CP, Halabi S, Clamon GH, Kaplan EB, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett ED
Cancer 101(2):370-378, 2004
7/15/2004

9081
GI Committee
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively-resected rectal cancer
Journal of Clinical Oncology 22 (1):166-174, 2004
1/15/2004

9081
GI Committee
Impact of Body Mass Index on outcomes and treatment-related toxicity in patients with Stage II and III Rectal Cancer: Findings from INT-0114
2/15/2004

9396
GI Committee
A comparison of laparoscopically assisted colectomy and open colectomy for colon cancer
5/13/2004

9583
GU Committee
A Phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in Androgen-Independent Prostate Cancer Patients: Results of CALGB 9583
Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable PS, Torti FM, Kaplan EB, Vogelzang NJ
Journal of Clinical Oncology 22:1025-1033, 2004
3/15/2004

90206
GU Committee
CALGB 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-VEGF antibody (bevacizumab, Avastin(r)) in metastatic renal cell carcinoma
Rini BI, Halabi S, Taylor JR, Small EJ, Schilsky RL
Clinical Cancer Research 10(8):2584-2586, 2004
4/15/2004

8461
Leukemia Correlative Sciences Committee
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461
9251
Lymphoma Committee
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B study 9251
Cancer 100(7):1438-1448, 2004
4/1/2004

9251
Lymphoma Committee
Burkitt leukemia and lymphoma are curable with short course of intensive chemotherapy
Rizzieri DA, Johnson JL, Larson RA
The American Journal of Oncology Review 38):475-481, 2004
8/2/2004

9332
Respiratory Committee
A Phase II Trial of Vinorelbine (NVB) plus Doxorubicin in relapsed small cell lung cancer
Johnson EA, Lake D, Herndon JE, Box JW, Lynch TJ, Green MR
2/14/2004

9495
Respiratory Committee
Induction chemoradiation and surgical resection for non-small cell lung carcinomas involving the superior sulcus: initial results of SWOG 9416 (Intergroup 0160/CALGB 9495)
The Journal of Thoracic and Cardiovascular Surgery 121(3):472-483, 2004
9/1/2004

39807
Respiratory Committee
Capecitabine (Xeloda) in malignant mesothelioma: a phase II trial by the CALGB
Otterson GA, Herndon JE, Watson D, Green MR, Kindler HL
Lung Cancer 44(2):251-259, 2004
5/1/2004

39809
Respiratory Committee
Randomized Phase II trial of Gemcitabine plus Irinotecan or Decetaxel in Stage IIIB or Stage IV NSCLC
Solid Tumor Correlative Sciences
Evaluation of microsatellite instability, HMLH1 expression and HMLH1 promoter hypermethylation in defining the phenotype of colorectal cancer: a study from CALGB 9865
Arnold CN, Goel A, Compton CC, Marcus V, Niedzwiecki D, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Biology and Therapy 3(1):73-78, 2004
1/5/2004

CALGB Manuscripts **Accepted but not yet published** in 2004 arranged by committee

9082
Breast Committee
A prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082
Journal of Clinical Oncology, 2004

9480
CCHO-Quality of Life
Phase III study of three different doses of suramin (NSC #34936) administered with a fixed dosing schedule in patients with advanced prostate cancer
Cancer, 2004

80001
GI Committee
Sentinel node staging of resectable colon cancer: results of CALGB 80001 a multicenter study
Annals of Surgery, 2004

99901
GU Committee
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer
Amin A, Halabi S, Werner CP, Small EJ, Stadler WM, Gelmann EP
Urologic Oncology, 2004
Pharmacology & Experimental Therapeutics
Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/pharmacodynamics in women with solid tumors
Clinical Cancer Research, 2004

Respiratory Committee
A Phase III trial evaluating the Combination of Cisplatin, Etoposide, radiation therapy with or without Tamoxifen in patients with Limited Stage Small Cell Lung Cancer
McClay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagreen S, Green M
The American Journal of Clinical Oncology, 2004

Respiratory Committee
A Phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusion (CALGB 9334)
Chest, 2004

Respiratory Committee
A phase II trial of 6-hydroxymethlyacyfulvene (MGI-114, Irofulven) in patients with relapsed or refractory non-small cell lung cancer
Sherman CA, Herndon JE, Green MR
Lung Cancer, 2004

Solid Tumor Correlative Sciences
Poor correspondence between clinical and pathologic staging in stage I non-small cell lung cancer: results from CALGB 9761, a prospective trial
Lung Cancer, 2004
## ASCO Submissions from CALGB for 2004

<table>
<thead>
<tr>
<th>Study</th>
<th>First Author</th>
<th>Title</th>
<th>ASCO#</th>
<th>Type of Presentn</th>
<th>#</th>
</tr>
</thead>
<tbody>
<tr>
<td>BREAST 9840</td>
<td>Seidman AD, Berry D, Cirrincione C, Harris LN, Dressler LG, Muss M, Naughton M, Norton L, Winer E, Hudis C</td>
<td>CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC</td>
<td>512</td>
<td>oral</td>
<td>3.</td>
</tr>
<tr>
<td>GI 89901</td>
<td>D. P. Ryan, D. Niedzwiecki, D. Hollis, B. E. Miedema, S. Wadler, J. E. Tepper, R. J. Mayer</td>
<td>A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901</td>
<td>3560</td>
<td>poster</td>
<td>7.</td>
</tr>
<tr>
<td>GI 8990+i</td>
<td>M. H. Kulke, D. Niedzwiecki, M. A. Tempero, D. R. Hollis, R. J. Mayer</td>
<td>A randomized Phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/trastuzumab in patients with metastatic pancreatic cancer (CALGB 89904)</td>
<td>4011</td>
<td>poster</td>
<td>8.</td>
</tr>
<tr>
<td>GU 90008</td>
<td>W. M. Stadler, S. Halabi, M. S. Ernstoff, R. Barrier, E. Davila, J. Picus, E. J. Small</td>
<td>A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B 90008</td>
<td>4515</td>
<td>oral</td>
<td>11.</td>
</tr>
<tr>
<td>Study</td>
<td>First Author</td>
<td>Title</td>
<td>ASCO#</td>
<td>Type of Presntn</td>
<td>#</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>--------</td>
<td>-----------------</td>
<td>---</td>
</tr>
<tr>
<td>GU</td>
<td>G. Philips, S. Halabi, B. Sanford, D. Bajorin, E. Small</td>
<td>Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: results of CALGB 90102</td>
<td>4540</td>
<td>poster</td>
<td>12.</td>
</tr>
</tbody>
</table>

Note: The table above lists studies and their corresponding authors, titles, ASCO numbers, types of presentations, and references for various medical conferences. The studies are categorized by their types (e.g., GU, LEUK, PET) and further detailed by their respective conference years. Each study entry includes the study name, first author, title of the study, ASCO number, type of presentation, and a unique identifier number.
<p>| RESP 59801 | P. K. Tohy, A. M. Mauer, D. Haraf, C. M. Rudin, P. C. Hoffman, M. K. Ferguson, L. Szeto, E. E. Vokes | A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC) | 7170 | oral | 24. |
| XXX 9480 | Daniel George | Prognostic significance of plasma Interleukin-6 (IL-6) level in patients with metastatic hormone-refractory prostate cancer (HRPC) | Not submitted after all |</p>
<table>
<thead>
<tr>
<th>Study (ASH #)</th>
<th>Authors</th>
<th>Title</th>
<th>ASH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>9191</td>
<td>Tallman MS, Kim HT, Schiffer CA, Apperlbau FR, Feusner JH, Ogden AK, Shepherd L, Willman CL, Bloomfield CA, Rowe JM, Larson RA, Wiernik PH, Martin G, Rayon C, del Serna J, Rivas C, Gonzalez-San Miguel JD, Deben G, Sanz MA</td>
<td>Microgranular variant (M3V) of acutre promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on Intergroup 0129 and pethema LPA96 and LPA99</td>
<td>394</td>
</tr>
<tr>
<td>9312</td>
<td>Rafael Santana-Davila, John Crowley, Brian Durie, Bart Barlogie, Philip Greipp, Brian Van Ness</td>
<td>Genetic polymorphisms associated with clinical outcome in the intergroup trial S9321, comparing high dose therapy with standard dose therapy for myeloma, on behalf of ECOG, SWOG, CALGB, and the Bank on a Cure</td>
<td>1495</td>
</tr>
<tr>
<td>Study</td>
<td>Authors</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>9712</td>
<td>Byrd JC, JG Gribben, B Peterson, G Lozanski, D Lucas, L Smith, RA Larson, MA Caligiuri, N Hereema</td>
<td>High risk genetic features predict earlier progression following chemoimmunotherapy with Fludarabine and Rituximab in chronic lymphocytic leukemia: results from CALGB 9712</td>
<td></td>
</tr>
<tr>
<td>10103</td>
<td>Flinn IW, Kumm E, Grever MR, Neuberg D, Dewald GW, Bennett JM, Paiette EM, Hussein MA, Moore DF, Tallman MS,</td>
<td>Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997</td>
<td></td>
</tr>
<tr>
<td>10103</td>
<td>Grever MR, Lucas DM, Dewald GW, Neuberg DS, Filinn IW, Tallman MS, Gribben JG, Byrd JC</td>
<td>Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia is adversely impacted by high risk genetic features: results from Intergroup E2997</td>
<td></td>
</tr>
<tr>
<td>19805</td>
<td>JC Byrd, BL Peterson, J Gabrilove, O Odenike, M Grever, K Rai, JW Vardiman, RA Larson</td>
<td>Sequential phase II studies of flavopiridol by 72-hour continuous infusion and one-hour intravenous bolus for the treatment of relapsed B-cell chronic lymphocytic leukemia: results from CALGB 19805</td>
<td></td>
</tr>
<tr>
<td>19902</td>
<td>Richard M Stone, MD, Barry Moser, PhD, Philip Schulman, MD, Robert C Barrier, MS, Jonathan E Kolitz, MD, Steven L Allen, MD, Wendy Stock, MD, Ilene A Galinsky, NPC, Hanna Khoury, MD, Richard A Larson, MD</td>
<td>A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902</td>
<td></td>
</tr>
</tbody>
</table>

**Lymphoma Committee**

<table>
<thead>
<tr>
<th>Study</th>
<th>Authors</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>50002</td>
<td>David L. Grinblatt, M.D., Jeffrey Johnson, Donna Niedzwiecki, Ph.D., David A. Rizzieri, M.D., Nancy Bartlett, M.D., Bruce D. Cheson, M.D.</td>
<td>Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL): CALGB study 50002</td>
</tr>
<tr>
<td>59901</td>
<td>Myron S. Czuczman, Pierluigi Porcu, Jeff Johnson, Donna Niedzwiecki, George Canellos, Bruce Cheson</td>
<td>CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL</td>
</tr>
<tr>
<td>59906</td>
<td>Sonali M. Smith, Jeffrey L. Johnson, Donna Niedzwiecki, J. Paul Eder, George Canellos, Bruce Cheson, Nancy L. Bartlett</td>
<td>Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: results of CALGB 59906, a phase II study of doxorubicin and topotecan</td>
</tr>
<tr>
<td>59909</td>
<td>Dorie Sher, Jeffrey Johnson, Mariah Siddiqui, Lloyd Damon, Charles Linker, Bruce Cheson, Wendy Stock</td>
<td>Eradication of minimal residual disease during treatment of mantle cell lymphoma: CALGB 59909</td>
</tr>
<tr>
<td>59909</td>
<td>Lloyd Damon, Donna Niedzwiecki, Bruce Cheson, David Hurd, Nancy Bartlett, Michael Kelly, Charles Linker, George Canellos</td>
<td>Intense immunochemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients with mantle cell lymphoma (MCL): CALGB 59909</td>
</tr>
<tr>
<td>Study</td>
<td>Authors</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>